Genistein (Synonyms: NPI 031L)

Name: Genistein
Brand: MedChemExpress
SKU: HY-14596
Rating: 5.0 (88 reviews)

Cat. No.: HY-14596 Purity: 99.82%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.

For research use only. We do not sell to patients.

CAS No. : 446-72-0

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 88 publication(s) in Google Scholar

Other Forms of Genistein:

Genistein-d₄ In-stock
Genistein (Standard) In-stock

88 Publications Citing Use of MCE Genistein

Flow Cytometry

: Genistein purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 21;10(1):349. [Abstract]; Analysis of the cellular uptake pathways of OVA PCD. Ethamilamiline (EIPA), genistein (GEN, 200 μM), and chlorpromazine (CPZ), pretreated for 4 h, subsequently incubated with FITC-labeled OVA PCD for 12 h were used to inhibit macropinocytosis, caveolin-mediated endocytosis, and clathrin-mediated endocytosis, respectively (n = 5).

: Genistein purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Apr 11. [Abstract]; Flow cytometry analysis of FDG MFI of neutrophils treated with dimethyl sulfoxide (DMSO) or different metabolites; the neutrophil FDG MFI ratio of metabolites relative to DMSO was calculated (n = 3).

: Genistein purchased from MedChemExpress. Usage Cited in: Nat Biomed Eng. 2024 Nov;8(11):1469-1482. [Abstract]; Cellular uptake pathway of different formulations. Cells were pretreated 2h with methyl-β-cyclodextrin (MCD), genistein (Gen, 200 µM), amiloride (AMI) or chlorpromazine (CPZ), to block lipid raft, caveolae-mediated endocytosis, micropinocytosis and clathrin-mediated endocytosis, respectively.

: Genistein purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Jan 14;6(7):2158-2172.; Transcytosis efficiency of FITC-labelled aPD/IND@MON-IgG and aPD/IND@MON-aANN at 30 min and 60 min in the transcytosis model pretreated with or without 200 μM genistein (endocytic pathway inhibitor) or 20 μM EXO1 (exocytic pathway inhibitor) for 2h.

: Genistein purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2020 Dec;15(12):1043-1052. [Abstract]; Flow cytometry measured the FITC MFI of CD11c+ BMDCs for BMDCs incubated with F7-PEI/FITC-OVA or F13-PEI/FITC-OVA, w/wo adding indicated endocytosis inhibitors (n = 3). BMDCs were incubated with genistein (700μM) for 30min before the addition of F7-PEI/OVA-FITC or F13-PEI/OVA-FITCNPs.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

EGFR

0.6 μM (IC₅₀, Cell Assay)

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	EC₅₀	108 μM Compound: 2	Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human A431 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
A-431	EC₅₀	278 μM Compound: 2	Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human A431 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
A-431	IC₅₀	1 x 10^-1 μg/mL Compound: 3	Inhibition of EGFR in human A431 cells Inhibition of EGFR in human A431 cells	[PMID: 1479375]
A-431	IC₅₀	7 x 10^-1 μg/mL Compound: 3	Inhibition of EGFR in human A431 cells Inhibition of EGFR in human A431 cells	[PMID: 1479375]
A549	IC₅₀	43.09 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 21129977]
A549	IC₅₀	64 μM Compound: Gen	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
AGS	IC₅₀	41.67 μM Compound: 1	Cytotoxicity against human AGS cells after 72 hrs by MTT assay Cytotoxicity against human AGS cells after 72 hrs by MTT assay	[PMID: 21129977]
ANN-1	IC₅₀	8 μM Compound: (1a) genistein	Cytotoxic effect on v-abl transformed murine ANN-1 cells Cytotoxic effect on v-abl transformed murine ANN-1 cells	[PMID: 8201603]
B16-F10	IC₅₀	79.21 μM Compound: 3	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay	[PMID: 27720556]
BALB/3T3	IC₅₀	183.9 μM Compound: 9	Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay Growth inhibition of BALB/c mouse cloned 3T3/A31 cells after 72 hrs by nigrosin assay	[PMID: 10096863]
BJ	EC₅₀	> 86.2069 μM Compound: 2	Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human BJ cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
BT-20	IC₅₀	46 μM Compound: Genistein	Antiproliferative activity against human BT20 cell line by MTT assay Antiproliferative activity against human BT20 cell line by MTT assay	[PMID: 16789737]
BV-2	IC₅₀	28.4 μM Compound: 6	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production	[PMID: 29482940]
BXPC-3	IC₅₀	30 μM Compound: Genistein	Antiproliferative activity against human BxPC3 cell line by MTT assay Antiproliferative activity against human BxPC3 cell line by MTT assay	[PMID: 16789737]
BXPC-3	IC₅₀	79 μM Compound: Gen	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Balb/MK	IC₅₀	9.1 μM Compound: Genistein	Tested for antiproliferative activity using mouse epidermal keratinocytes cell line (BALB/MK) Tested for antiproliferative activity using mouse epidermal keratinocytes cell line (BALB/MK)	[PMID: 7608909]
C8166	CC₅₀	36.2 μg/mL Compound: 7	Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human C8166 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 24794743]
C8166	EC₅₀	13.9 μg/mL Compound: 7	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis	[PMID: 24794743]
COLO 201	IC₅₀	73 μM Compound: Gen	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
COLO357	IC₅₀	50 μM Compound: Genistein	Antiproliferative activity against human COLO357 cell line by MTT assay Antiproliferative activity against human COLO357 cell line by MTT assay	[PMID: 16789737]
Caco-2	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay	[PMID: 21129977]
DLD-1	IC₅₀	50 μM Compound: 51	Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability by MTS assay Antiproliferative activity against human DLD-1 cells assessed as reduction in cell viability by MTS assay	[PMID: 33445154]
DU-145	ED₅₀	2.39 μg/mL Compound: 5	Cytotoxicity against human DU145 cells after 6 days by MTT assay Cytotoxicity against human DU145 cells after 6 days by MTT assay	[PMID: 12088420]
DU-145	IC₅₀	47.29 μM Compound: 1	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 21129977]
DU-145	IC₅₀	> 100 μM Compound: Genistein	Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-independent DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
HCT-116	IC₅₀	34.9 μM Compound: 1	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 21129977]
HEK293	IC₅₀	16.5 μM Compound: 21	Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol Inhibition of human recombinant 17beta-HSD2 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol	[PMID: 18533708]
HEK293	IC₅₀	2.21 μM Compound: 21	Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol Inhibition of human recombinant 17beta-HSD1 expressed in HEK293 cell lysate assessed as conversion of radiolabeled estrone to estradiol	[PMID: 18533708]
HEK293	IC₅₀	22 μM Compound: genistein	Antagonist activity at human recombinant LXRbeta expressed in HEK293 cells by luciferase reporter gene assay Antagonist activity at human recombinant LXRbeta expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 18343126]
HEK293	IC₅₀	25.12 μM Compound: Genistein	Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay Inhibition of EGFR (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay	[PMID: 25205190]
HEK293	IC₅₀	31 μM Compound: genistein	Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay Antagonist activity at human recombinant LXRalpha expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 18343126]
HEK293	IC₅₀	58.18 μM Compound: Genistein	Inhibition of Fyn (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay Inhibition of Fyn (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay	[PMID: 25205190]
HEK293	IC₅₀	67.99 μM Compound: Genistein	Inhibition of Bmx (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay Inhibition of Bmx (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay	[PMID: 25205190]
HEK293	IC₅₀	> 100 μM Compound: Genistein	Inhibition of Src (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay Inhibition of Src (unknown origin) expressed in HEK293 cells assessed as decrease in phosphorylation by chemiluminescence assay	[PMID: 25205190]
HT-29	IC₅₀	50 μM Compound: Gen	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HT-29	IC₅₀	52.78 μM Compound: 1	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 21129977]
HUVEC	IC₅₀	88 μM Compound: 13	Cytotoxicity against HUVEC after 24 hrs by MTT assay Cytotoxicity against HUVEC after 24 hrs by MTT assay	[PMID: 17591441]
HeLa	EC₅₀	4.1 nM Compound: genistein	Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta. Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta.	[PMID: 11906280]
HeLa	EC₅₀	48 nM Compound: genistein	Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha. Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha.	[PMID: 11906280]
HeLa	EC₅₀	73 nM Compound: genistein	Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay	[PMID: 16610787]
HeLa	EC₅₀	956 nM Compound: genistein	Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM	[PMID: 16610787]
HepG2	EC₅₀	67.6945 μM Compound: 2	Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human HepG2 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
HepG2	IC₅₀	> 100 μM Compound: Genistein	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26896708]
Hs-578T	ED₅₀	3.5 μg/mL Compound: 5	Cytotoxicity against human Hs 578T cells after 6 days by MTT assay Cytotoxicity against human Hs 578T cells after 6 days by MTT assay	[PMID: 12088420]
Hs746T	ED₅₀	5.82 μg/mL Compound: 5	Cytotoxicity against human Hs 746T cells after 6 days by MTT assay Cytotoxicity against human Hs 746T cells after 6 days by MTT assay	[PMID: 12088420]
Huh-7	CC₅₀	> 50 μM Compound: 23	Cytotoxicity against human Huh7.5.1 cells by MTT assay Cytotoxicity against human Huh7.5.1 cells by MTT assay	[PMID: 22445328]
Huh-7	EC₅₀	14.4 μM Compound: 23	Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay	[PMID: 22445328]
Huh-7	IC₅₀	20 μM Compound: Genistein	Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei ANKA expressing GFP infected in human HuH7 cells assessed as inhibition of parasite development after 24 hrs by qRT-PCR analysis Antiplasmodial activity against liver sporozoite stage of Plasmodium berghei ANKA expressing GFP infected in human HuH7 cells assessed as inhibition of parasite development after 24 hrs by qRT-PCR analysis	[PMID: 24125849]
Ishikawa	IC₅₀	0.51 μM Compound: genistein	Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay Estrogenic activity in human Ishikawa cells assessed as induction of alkaline phosphatase activity after 4 days by para-nitrophenol release assay	[PMID: 12502307]
K562	IC₅₀	17.56 μM Compound: 1	Growth inhibition of K562 cells by XTT assay after 5 days Growth inhibition of K562 cells by XTT assay after 5 days	[PMID: 17411092]
KB	ED₅₀	6.7 μg/mL Compound: NSC-36586	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 469554]
KOPN-8	EC₅₀	> 86.2069 μM Compound: 2	Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human KOPN8 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
L02	IC₅₀	> 100 μM Compound: Genistein	Cytotoxicity against human LO2 cells after 48 hrs by MTT assay Cytotoxicity against human LO2 cells after 48 hrs by MTT assay	[PMID: 26896708]
LN-229	IC₅₀	44 μM Compound: Gen	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LNCaP	IC₅₀	10 μM Compound: Genistein	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 29456113]
LNCaP	IC₅₀	24 μM Compound: Genistein	Antiproliferative activity against human LNCAP cells after 72 hrs by MTS assay Antiproliferative activity against human LNCAP cells after 72 hrs by MTS assay	[PMID: 29456113]
LNCaP	IC₅₀	30.65 μM Compound: 1	Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay	[PMID: 21129977]
LNCaP	IC₅₀	31.7 μM Compound: Genistein	Antiproliferative activity against human LNCAP cells after 72 hrs in presence of enzalutamide by MTS assay Antiproliferative activity against human LNCAP cells after 72 hrs in presence of enzalutamide by MTS assay	[PMID: 29456113]
LNCaP	IC₅₀	37.4 μM Compound: Genistein	Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
LNCaP	IC₅₀	65 μM Compound: Genistein	Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human LNCap cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 60 mins by fluorescence based method Inhibition of chymotrypsin-like activity of human 26S proteasome extracted from human LNCap cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 60 mins by fluorescence based method	[PMID: 30776692]
LNCaP-Clone-FGC	ED₅₀	25.45 μg/mL Compound: 5	Cytotoxicity against human LNCaP-FGC cells after 6 days by MTT assay Cytotoxicity against human LNCaP-FGC cells after 6 days by MTT assay	[PMID: 12088420]
LoVo	IC₅₀	15.88 μM Compound: 1	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21129977]
MCF7	GI₅₀	10 μM Compound: 2	Antiproliferative activity against estrogen receptor expressing human MCF7 cells Antiproliferative activity against estrogen receptor expressing human MCF7 cells	[PMID: 19818612]
MCF7	IC₅₀	1 x 10^-6 M Compound: genistein	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20813524]
MCF7	IC₅₀	11 μM Compound: genistein	Anti-proliferative activity against estrogen-responsive human breast cancer cell line MCF-7 in the presence of ER at a 10e-4 uM concentration of estradiol Anti-proliferative activity against estrogen-responsive human breast cancer cell line MCF-7 in the presence of ER at a 10e-4 uM concentration of estradiol	[PMID: 8784443]
MCF7	IC₅₀	15.1 μM Compound: (1a) genistein	Cytotoxic effect on MCF-7 human breast carcinoma cells Cytotoxic effect on MCF-7 human breast carcinoma cells	[PMID: 8201603]
MCF7	IC₅₀	26 μM Compound: genistein	Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs	[PMID: 10075742]
MCF7	IC₅₀	50 nM Compound: Genistein	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	62.71 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 21129977]
MCF7	IC₅₀	77 μM Compound: genistein	Inhibition of 10e-4 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation Inhibition of 10e-4 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation	[PMID: 8784443]
MCF7	IC₅₀	8.8 μM Compound: 28	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MCF7	IC₅₀	> 30 μM Compound: genistein	Cytotoxicity against human MCF7 cells after 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs	[PMID: 10075742]
MDA-MB-231	IC₅₀	43 μM Compound: Gen	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-436	GI₅₀	17 μM Compound: 2	Antiproliferative activity against estrogen receptor expressing human MDA-MB-436 cells Antiproliferative activity against estrogen receptor expressing human MDA-MB-436 cells	[PMID: 19818612]
MDCK	IC₅₀	6.9 μM Compound: 28	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
Melan-a	IC₅₀	57.83 μM Compound: 6	Inhibition of melanin formation in mouse Melan-a cells after 5 days by ELISA Inhibition of melanin formation in mouse Melan-a cells after 5 days by ELISA	[PMID: 20022495]
NCI-H460	IC₅₀	47 μM Compound: Gen	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NIH3T3	EC₅₀	4.4 μM Compound: Genistein	Agonist activity at CFTR-deltaF508 mutant expressed in NIH3T3 cells assessed as increase in forskolin-stimulated current Agonist activity at CFTR-deltaF508 mutant expressed in NIH3T3 cells assessed as increase in forskolin-stimulated current	[PMID: 18595696]
NIH3T3	IC₅₀	24 μM Compound: (1a) genistein	Cytotoxic effect on 3T3 cells Cytotoxic effect on 3T3 cells	[PMID: 8201603]
Neutrophil	IC₅₀	0.54 μg/mL Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation after 5 mins	[PMID: 21353775]
Neutrophil	IC₅₀	0.69 μM Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced superoxide anion production treated 5 mins before FMLP addition measured after 10 mins Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced superoxide anion production treated 5 mins before FMLP addition measured after 10 mins	[PMID: 23822585]
Neutrophil	IC₅₀	1.11 μM Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLF/cytochalasin B-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins by spectrophotometric analysis Antiinflammatory activity in human neutrophils assessed as inhibition of fMLF/cytochalasin B-induced superoxide anion generation preincubated for 5 mins followed by fMLF addition after priming with CB for 3 mins by spectrophotometric analysis	[PMID: 32359855]
Neutrophil	IC₅₀	6.72 μM Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced elastase release treated 5 mins before FMLP addition Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP-induced elastase release treated 5 mins before FMLP addition	[PMID: 23822585]
Neutrophil	IC₅₀	6.99 μg/mL Compound: Genistein	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release after 5 mins	[PMID: 21353775]
PANC-1	IC₅₀	87 μM Compound: Gen	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PC-3	IC₅₀	50 μM Compound: Genistein	Antiproliferative activity against human PC3 cell line by MTT assay Antiproliferative activity against human PC3 cell line by MTT assay	[PMID: 16789737]
PC-3	IC₅₀	65.17 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21129977]
PC-3	IC₅₀	68.6 μM Compound: Genistein	Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay Cytotoxicity against human androgen-independent PC3 cells assessed as cell cell viability after 3 days by WST-1 cell proliferation assay	[PMID: 26341135]
Peritoneal macrophage	IC₅₀	16.87 μM Compound: 120	Antiinflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as TNF-alpha level Antiinflammatory activity against LPS-stimulated mouse peritoneal macrophage assessed as TNF-alpha level	[PMID: 37683361]
RAW	IC₅₀	18.1 μM Compound: genistein	Inhibition of 1 ug/ml LPS-stimulated TNFalpha accumulation in RAW 264 cells after 24 hrs Inhibition of 1 ug/ml LPS-stimulated TNFalpha accumulation in RAW 264 cells after 24 hrs	[PMID: 17320246]
RAW264.7	IC₅₀	11.4 μM Compound: Genistein	Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-induced osteoclast differentiation after 4 to 5 days by TRAP assay Antiosteoporotic activity in mouse RAW264.7 cells assessed as inhibition of RANKL-induced osteoclast differentiation after 4 to 5 days by TRAP assay	[PMID: 28169537]
RAW264.7	IC₅₀	19.1 μM Compound: Genistein	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production treated 2 hrs before LPS challenge measured after 24 hrs by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production treated 2 hrs before LPS challenge measured after 24 hrs by ELISA	[PMID: 21288727]
RAW264.7	IC₅₀	26 μM Compound: Genistein	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production after 24 hrs by Griess reagent	[PMID: 20363145]
RAW264.7	IC₅₀	26.5 μM Compound: Genistein	Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay Inhibition of LPS-induced TNFalpha release in mouse RAW264.7 cells pretreated 1 hr before LPS challenge by enzyme immunoassay	[PMID: 19278854]
RAW264.7	IC₅₀	> 1 μM Compound: 19	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pretreated for 1 hr followed by LPS-stimulation and measured after 24 hrs by Griess assay	[PMID: 29932657]
RAW264.7	IC₅₀	> 50 μM Compound: 10	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25592708]
SEM	EC₅₀	59.338 μM Compound: 2	Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SEM cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
SH-SY5Y	EC₅₀	1.7 nM Compound: genistein	Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta	[PMID: 11906280]
SK-BR-3	EC₅₀	403 μM Compound: 2	Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human SKBR3 cells overexpressing ErbB in complete medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
SK-BR-3	EC₅₀	97 μM Compound: 2	Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay Antiproliferative activity against human SKBR3 cells overexpressing ErbB in serum-free medium assessed as cell viability after 48 hrs by WST-1 assay	[PMID: 24456004]
SK-BR-3	IC₅₀	96.7 μM Compound: 1	Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay Cytotoxicity against human SKBR3 cells after 72 hrs by SRB assay	[PMID: 21129977]
SK-MEL-2	IC₅₀	36 μM Compound: Gen	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SUP-B15	EC₅₀	> 86.2069 μM Compound: 2	Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human SUP-B15 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Sf9	IC₅₀	30 μM Compound: 10	Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintillation counting method Inhibition of His6-tagged human recombinant DNMT1 expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintillation counting method	[PMID: 25406944]
Sf9	IC₅₀	> 100 μM Compound: 10	Inhibition of His6-tagged human recombinant DNMT3A/DNMT3L expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintillation counting method Inhibition of His6-tagged human recombinant DNMT3A/DNMT3L expressed in insect Sf9 cells assessed as reduction in DNA methyltransferase activity using 5'-biotinylated 45-bp unmethylated or hemimethylated oligonucleotide substrates and [3H]-AdoMet by liquid scintillation counting method	[PMID: 25406944]
T47D	IC₅₀	48 μM Compound: Gen	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T98G	IC₅₀	89.41 μM Compound: 1	Cytotoxicity against human T98G cells after 72 hrs by SRB assay Cytotoxicity against human T98G cells after 72 hrs by SRB assay	[PMID: 21129977]
U-87MG ATCC	IC₅₀	55 μM Compound: Gen	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-937	IC₅₀	48 μM Compound: 5	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	72 μM Compound: 5	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	> 100 μM Compound: 5	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]
UoC-B1	EC₅₀	35.6958 μM Compound: 2	Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay Antiproliferative activity against human UOCB1 cells after 72 hrs by CelTiter-Glo assay	[PMID: 29407975]
Ventricular myocyte	IC₅₀	11 μM Compound: Genistein	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]
Ventricular myocyte	IC₅₀	20 μM Compound: Genistein	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]
Vero	CC₅₀	> 50 μM Compound: 64	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 33539089]
Vero	IC₅₀	32.9 μM Compound: Genistein	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 16441066]
WiDr	IC₅₀	27.7 μM Compound: (1a) genistein	Cytotoxic effect on WiDr human colon cells Cytotoxic effect on WiDr human colon cells	[PMID: 8201603]

In Vitro

Genistein inhibits serum-stimulated growth of MCF-7 and T47D ER⁺ cells with IC₅₀ values of 7.6 and 8.7 μg/mL by dye exclusion, respectively, and 8.7 and 10.6 μg/mL by [³H]thymidmne incorporation, respectively. These values are similar to the IC₅₀ values of 9.4 and 7 μg/mL for MCF-7 and T47D ER⁺ cells, respectively, obtained with the MTT assay. Additionally, Genistein at concentrations up to 20 μg/mL does not alter MTT mitochondrial reduction when compared to control cells in an 8 h incubation period. Furthermore, neither biochanin A or daidzein are found to interfere with the MTT assay at IC₅₀ concentrations. Therefore, the MTT assay is valid for determining growth inhibition by Genistein at concentrations under 20 μg/mL in the systems studied^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bisphenol A (BPA) treatment alone and combined with Genistein had no significant effect on the protein expression of LC3II and PPARα in liver of STD- or HFD-fed rats (P>0.05; P>0.05). Significant decreasing of the protein expression of PPARγ in liver is observed when Genistein is added to rats, compared to either HFD group or HFD-BPA group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

270.24

Formula

C₁₅H₁₀O₅

CAS No.

446-72-0

Appearance

Solid

Color

White to yellow

SMILES

OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1

Structure Classification

Initial Source

Microorganisms

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (370.04 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7004 mL	18.5021 mL	37.0041 mL
5 mM	0.7401 mL	3.7004 mL	7.4008 mL
10 mM	0.3700 mL	1.8502 mL	3.7004 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.75 mg/mL (13.88 mM); Clear solution

This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3 mg/mL (11.10 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 3 mg/mL (11.10 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (18.50 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.82%

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (247 KB) HNMR (259 KB) RP-HPLC (246 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Peterson G, et al. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996 Oct;7(10):1345-51. [Content Brief]

[2]. Ding S, et al. Environmentally Relevant Dose of Bisphenol A Does Not Affect Lipid Metabolism and Has No Synergetic or Antagonistic Effects on Genistein's Beneficial Roles on Lipid Metabolism. PLoS One. 2016 May 12;11(5):e0155352. [Content Brief]

Cell Assay ^[1]	The IC₅₀ values for Genistein are determined by the MTT assay. Briefly, the MTT assay is a colorimetric assay that is based on the ability of living but not dead cells to reduce a tetrazolium-based compound to a blue formazan product. The formazan crystals are solubilized in DMSO, and the absorbance is measured at 540 nm. The absorbance at 540 nm is proportional to the number of viable cells. The lC₅₀ values obtained with the MTT assay are compared with the lC₅₀ values obtained by counting viable cells using trypan blue dye exclusion and by tritiated thymidine incorporation into DNA^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]^[3]	Mice^[2] Balb/c male mice are used. Genistein is administered as follows: On days 1-30, Genistein once daily, interaperitoneally injecting. Morphine plus Genistein is administered as follows: On days 1-30, Genistein once daily plus morphine, interaperitoneally injecting (17, 18). The same volume of saline is administered. Mice are randomly divided into 8 groups (n=6). 1) Normal saline group (1 mL DW/daily); 2) Morphine treated group; 3) Genistein 1 mg/kg treated group; 4) Genistein 2 mg/kg treated group 5) Genistein 4 mg/kg treated group; 6) Morphine plus Genistein 1 mg/kg treated group; 7) Morphine plus Genistein 2 mg/kg treated group; 8) Morphine plus Genistein 4 mg/kg treated group. Rats^[3] Male 8-week-old Wistar rats (150-180g) are used. After one week acclimation, all rats are randomly divided into 8 groups with 10 rats per group and treated for 35 weeks as follows: (1) STD group is fed with rodent standard chow diet (STD); (2) STD-BPA group is fed with STD and administered with BPA (50 μg/kg/day); (3) STD-(BPA+G) group is fed with STD and administered with BPA (50 μg/kg/day) plus Genistein (10 mg/kg/day); (4) STD-G group is fed with STD and administered with Genistein (10 mg/kg/day); (5) HFD group received high-fat diet (HFD); (6) HFD-BPA group is fed with HFD and administered with BPA (50 μg/kg/day); (7) STD-(BPA+G) group is fed with HFD and administered with BPA (50 μg/kg/day) plus Genistein (10 mg/kg/day); (8) HFD-G group is fed with HFD and administrated with Genistein (10 mg/kg/day). All the male genitors are treated for 35 weeks consecutively. The details of BPA (50 μg/kg/day) and Genistein (10 mg/kg/day) treatment methods have been described previously: BPA is dissolved in corn oil and diluted with three stock solutions (20, 40, 80, and 120 μg/mL). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Peterson G, et al. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ. 1996 Oct;7(10):1345-51. [Content Brief] [2]. Ding S, et al. Environmentally Relevant Dose of Bisphenol A Does Not Affect Lipid Metabolism and Has No Synergetic or Antagonistic Effects on Genistein's Beneficial Roles on Lipid Metabolism. PLoS One. 2016 May 12;11(5):e0155352. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.7004 mL	18.5021 mL	37.0041 mL	92.5104 mL
	5 mM	0.7401 mL	3.7004 mL	7.4008 mL	18.5021 mL
	10 mM	0.3700 mL	1.8502 mL	3.7004 mL	9.2510 mL
	15 mM	0.2467 mL	1.2335 mL	2.4669 mL	6.1674 mL
	20 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6255 mL
	25 mM	0.1480 mL	0.7401 mL	1.4802 mL	3.7004 mL
	30 mM	0.1233 mL	0.6167 mL	1.2335 mL	3.0837 mL
	40 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	50 mM	0.0740 mL	0.3700 mL	0.7401 mL	1.8502 mL
	60 mM	0.0617 mL	0.3084 mL	0.6167 mL	1.5418 mL
	80 mM	0.0463 mL	0.2313 mL	0.4626 mL	1.1564 mL
	100 mM	0.0370 mL	0.1850 mL	0.3700 mL	0.9251 mL

Genistein Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Genistein446-72-0NPI 031LEGFRAutophagyApoptosisEndogenous MetaboliteEpidermal growth factor receptorErbB-1HER1Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Genistein (Synonyms: NPI 031L)

Customer Review

Other Forms of Genistein:

Genistein Related Antibodies

88 Publications Citing Use of MCE Genistein

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Genistein Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Genistein Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report